Sentence examples for relevant panel from inspiring English sources

To correlate these responses with novel preimplantation processing methods to reduce cellularity, both a relevant panel reactive antibody assay and a chronic implantation animal model are necessary.

The estimation of the diagnostic sensitivity and specificity of a test should ideally be derived from testing a statistically relevant panel of animals.

The results of such studies were used to define this smaller, more relevant panel of genomic loci, which includes LOH markers that had mutations in at least 20% of the surgical EAC specimens.

We chose a clinically relevant panel of 4 SNP targets (FV 1691 G-A [ 2], PT 20210 G-A [ 3], MTHFR 677 C-T [ 4] and MTHFR 1298 A-C [ 5]) that are associated with coagulopathic disease and that are routinely tested for in our laboratory using commercial FDA-cleared kits.

That's because any given SXSW-prime hour (9 30 a.m., 11 a.m., 3 30 p.m. and 5 p.m). has dozens of relevant panels for me to choose from.

We present below a representative example of how we should have depicted the relevant panels by reproducing both the original published gel scan for Figure 5A (RING1B pull-down blotted with anti-RING1B antibody) and a revised panel.

Study subjects included the first 2,079 patients who had hereditary cancer panel results reported by our laboratory between March 2012 and May 2013, prior to the inclusion of BRCA1 and BRCA2 on relevant panels (Ambry Genetics, Aliso Viejo, CA).

These results suggest that this approach can meet a need in the clinical lab where moderate numbers of samples can be tested against specific clinically relevant panels of SNP targets.

However, the oligomeric IgM-BCR opened when we co-expressed nLyn-Syk-KD together with either the GFP- SH2 2 or the kinase neGFP- SH2 2-Syk-K- corsthects that alone did not alter the IgM-BCR conformation (compare relevant panels and bars in Figure 6A,B).

It is routine practice in research and development that microarray studies be employed in preliminary investigations, particularly in molecular oncology, in order to identify statistically relevant panels in which to re-evaluate and further refine in the clinical setting [ 23- 25].

He was voted out by the relevant Senate panel in September, but his nomination has stalled.